DOP011 Risk of opportunistic infection in healthcare personnel with inflammatory bowel disease: a case-control study of the GETAID
Gagniere C.*1, Bourrier A.2, Seksik P.2, Gornet J.-M.3, Dewit O.4, Nancey S.5, Altwegg R.6, Abitbol V.7, Laharie D.8, Reenaers C.9, Buisson A.10, Nachury M.11, Viennot S.12, Vuitton L.13, Stefanescu C.14, Marteau P.15, Bouguen G.16, Cosnes J.2, Amiot A.1
1Henri Mondor Hospital, Gastroenterology, Creteil, France 2APHP St. Antoine Hospital, Department of Gastroenterology, Paris, France 3Hospital Saint-Louis, Department of Gastroenterology, Paris, France 4UCL Saint-Luc, Department of Gastroenterology, Brussels, Belgium 5Hospital Edouard Herriot, Department of Gastroenterology and Hepatology, Lyon, France 6CHU Montpellier Saint Eloi Hospital, Department of Gastroenterology, Montpellier, France 7Cochin Hospital, Department of Gastroenterology, Paris, France 8CHU Bordeaux, Department of Gastroenterology, Bordeaux, France 9CHU Liège, Sart Tilman, Department of Gastroenterology, Liège, Belgium 10CHU Estaing, Department of Gastroenterology, Clermont-Ferrand, France 11CHRU Lille, Department of Gastroenterology, Lille, France 12Hospital Cote de Nacre, Department of Gastroenterology, Caen Cede, France 13CHU Besancon, Department of Gastroenterology and Hepatology, Besançon, France 14APHP Beaujon, Department of Gastroenterology, Clichy, France 15Hospital Lariboisière, Department of Gastroenterology, Paris, France 16CHU Pontchaillou, Department of Gastroenterology, Rennes, France
The increased use of immunomodulators and biological agents for the treatment of patients with inflammatory bowel disease (IBD) is associated with a key safety concern considering potential opportunistic infection. Healthcare personnel were thought to be at substantial risk for acquiring such infection due to daily and close interactions with infected patients and asymptomatic carriers of pathogens.
We performed a retrospective observational study, collecting data from the GETAID, between January 2015 and June 2016, on all 482 consecutive patients with IBD (68.5% with Crohn's disease, 28.4% with ulcerative colitis and 3.1% with IBD undetermined) who work as healthcare personnel (27.2% of physicians, 33.0% of nurses; 13.1% of nurses' aides and 26.7% of other healthcare personnel), in 17 tertiary centers in France and Belgium. We selected a control group of patients with IBD from the monocentric MICISTA database. Controls were matched on age (± 2.5 years), sex, IBD type and date of IBD diagnosis (± 2.5 years). Opportunistic infection was defined as (1)
482 patients (126 male; median age: 24.0 [IQR 19.9–32.1] years) were included in the present study. The median follow-up period was 9.3 [4.6–16.2] years. A total of 60 opportunistic infection was recorded including 10
Although there is an higher exposure to potential pathogens in healthcare personnel, this is not associated with an higher risk of opportunistic infection as compared with controls. Prospective studies are needed to confirm that the level of occupational exposure to potential pathogens should not be taken into account when discussing the introduction of immunomodulator or biological agents.